All In Biotech

Drug Trial Radar · NCT04436497

HEALEY ALS Platform Trial - Regimen A Zilucoplan

Last checked: Nov 20, 2026Latest source record: Jul 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 162 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

162

Actual

Start

Jul 29, 2020

Primary completion

Apr 13, 2022

Study completion May 4, 2022

Sponsor

Lead sponsor
Merit E. Cudkowicz, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ra Pharmaceuticals
First posted
Jun 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen A will evaluate the safety and efficacy of a single study drug, zilucoplan, in participants with ALS.

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • ZilucoplanDrug

    Drug: Zilucoplan Administration: Subcutaneous injection Dosage: 0.3mg/kg administered daily

  • Matching PlaceboDrug

    Drug: Matching Placebo Administration: Subcutaneous injection Dosage: Daily subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease Progression as Assessed by the ALSFRS-R Total ScoreTime frame: Baseline through 24 Weeks
  2. Mortality Event RateTime frame: Baseline through 24 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Healey Center for ALS at Mass General

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.